HUP0300725A2 - Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors - Google Patents

Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Info

Publication number
HUP0300725A2
HUP0300725A2 HU0300725A HUP0300725A HUP0300725A2 HU P0300725 A2 HUP0300725 A2 HU P0300725A2 HU 0300725 A HU0300725 A HU 0300725A HU P0300725 A HUP0300725 A HU P0300725A HU P0300725 A2 HUP0300725 A2 HU P0300725A2
Authority
HU
Hungary
Prior art keywords
insulin resistance
resistance syndrome
treatment
cgmp pde5
selective cgmp
Prior art date
Application number
HU0300725A
Other languages
Hungarian (hu)
Inventor
David Albert Fryburg
Earl Michael Gibbs
Nandan Parmanand Koppiker
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0030649A external-priority patent/GB0030649D0/en
Priority claimed from GB0106468A external-priority patent/GB0106468D0/en
Priority claimed from GB0106465A external-priority patent/GB0106465D0/en
Priority claimed from GB0117134A external-priority patent/GB0117134D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0300725A2 publication Critical patent/HUP0300725A2/en
Publication of HUP0300725A3 publication Critical patent/HUP0300725A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Egy szelektív cGMP PDE5 inhibitornak vagy egy gyógyászatikompozíciójának alkalmazása az inzulinrezisztencia-szindróma gyógyító,enyhítő vagy megelőző kezelésében használható gyógyszerelőállításában, ahol az inzulinrezisztencia-szindróma jelentése, hogyegy betegnél egyszerre áll fenn a következő kórképek közül legalábbkettő: diszlipidémia; hipertenzió; 2. típusú diabétesz mellitusz,károsult glükóz tolerancia (IGT), vagy a családban előfordulódiabétesz; hiperurikémia és/vagy köszvény; prokoaguláns állapot,ateroszklerózis; vagy törzsi elhízás, és ahol az inzulinrezisztencia-szindrómának vagy az inzulinrezisztencia-szindróma egyéniaspektusainak kezelésében a vegyület vagy kompozíció alkalmazhatóönmagában vagy más ágensekkel kombinálva. ÓThe use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the production of a medicine for the curative, mitigating or preventive treatment of insulin resistance syndrome, where insulin resistance syndrome means that a patient has at least two of the following pathologies at the same time: dyslipidemia; hypertension; Type 2 diabetes mellitus, impaired glucose tolerance (IGT), or family history of diabetes; hyperuricemia and/or gout; procoagulant condition, atherosclerosis; or familial obesity, and wherein the compound or composition may be used alone or in combination with other agents in the treatment of insulin resistance syndrome or individual aspects of insulin resistance syndrome. HE

HU0300725A 2000-08-11 2001-08-06 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors HUP0300725A3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22492800P 2000-08-11 2000-08-11
GB0030649A GB0030649D0 (en) 2000-12-15 2000-12-15 Treatment of the insulin resistance syndrome
US26608301P 2001-02-02 2001-02-02
GB0106468A GB0106468D0 (en) 2001-03-15 2001-03-15 Treatment of diabetes mellitus
GB0106465A GB0106465D0 (en) 2001-03-15 2001-03-15 Treatment of the insulin resistance syndrome
GB0117134A GB0117134D0 (en) 2001-07-13 2001-07-13 Treatment of the insulin resistance syndrome
PCT/IB2001/001428 WO2002013798A2 (en) 2000-08-11 2001-08-06 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Publications (2)

Publication Number Publication Date
HUP0300725A2 true HUP0300725A2 (en) 2003-11-28
HUP0300725A3 HUP0300725A3 (en) 2005-11-28

Family

ID=27546614

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300725A HUP0300725A3 (en) 2000-08-11 2001-08-06 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Country Status (9)

Country Link
EP (1) EP1307183A2 (en)
JP (1) JP2004506009A (en)
KR (1) KR20030023747A (en)
CN (1) CN1446084A (en)
AU (1) AU2001276607A1 (en)
CA (1) CA2419033A1 (en)
HU (1) HUP0300725A3 (en)
IL (1) IL154158A0 (en)
WO (1) WO2002013798A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527476A (en) * 2001-02-02 2004-09-09 ファイザー・インク Treatment of diabetes mellitus
JP4142356B2 (en) 2001-07-05 2008-09-03 オイクロ ヨーロピアン コントラクト リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト PP2C substrate
DE10135815A1 (en) * 2001-07-23 2003-02-06 Bayer Ag Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
EP1444009A1 (en) 2001-11-02 2004-08-11 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
BR0307595A (en) * 2002-02-07 2005-02-01 Pfizer Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovarian syndrome
JP2004018524A (en) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg Method for treating arteriosclerosis
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
EP1605925A1 (en) * 2003-03-17 2005-12-21 Pfizer Products Inc. Treatment of type 1 diabetes with pde5 inhibitors
UA80871C2 (en) * 2003-04-29 2007-11-12 Pfizer Ltd 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
ATE433978T1 (en) 2003-04-29 2009-07-15 Pfizer Ltd 5,7-DIAMINOPYRAZOLO 4,3-D PYRIMIDINES FOR USE IN THE TREATMENT OF HYPERTENSION
AU2004269923B2 (en) 2003-09-05 2010-05-13 Takeda Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US7569572B2 (en) 2004-04-07 2009-08-04 Pfizer Inc Pyrazolo[4,3-D]pyrimidines
CA2599376C (en) 2005-03-08 2014-05-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
WO2007010337A2 (en) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
PL2152663T3 (en) 2007-06-04 2014-09-30 Ben Gurion Univ Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
AT512084A1 (en) 2011-10-20 2013-05-15 Univ Wien Tech DIAZABICYCLO AND DIAZASPIRO ALKAN DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PL2854841T3 (en) 2012-06-04 2017-08-31 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
AU2013344753B2 (en) * 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
AU2014202625B2 (en) * 2013-05-14 2018-11-08 Scimar Ltd. Hepatic insulin sensitizing substance and test meal for insulin sensitization
EP3065723B1 (en) 2013-11-05 2020-09-23 Ben Gurion University of the Negev Research and Development Authority Compounds for the treatment of diabetes and disease complications arising from same
KR20190122706A (en) 2017-03-09 2019-10-30 다이어메디카 인코포레이티드 Dosage form of tissue kallikrein 1
MX2017016930A (en) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Method of treatment of diabetic foot ulcers.
KR102068299B1 (en) * 2018-12-21 2020-01-20 한국기초과학지원연구원 A pharmaceutical composition for prevention or treatment of metabolic disease comprising CYP4A inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
ES2244979T3 (en) * 1995-12-28 2005-12-16 Fujisawa Pharmaceutical Co., Ltd. DERIVATIVES OF BENZIMIDAZOL.
NZ338075A (en) * 1997-04-25 2000-10-27 Pfizer Ltd Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction
BR9810456A (en) * 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Sulfonamide compound, method for obtaining it and its pharmaceutical use
WO1999051574A1 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
CN1335847A (en) * 1998-12-04 2002-02-13 藤泽药品工业株式会社 Sulfonamide compounds and uses thereof as medicines
AU765128B2 (en) * 1999-03-22 2003-09-11 Bristol-Myers Squibb Company Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
DE19944161A1 (en) * 1999-09-15 2001-03-22 Bayer Ag New combination for the treatment of sexual dysfunction
PT1088824E (en) * 1999-09-30 2004-04-30 Pfizer Prod Inc BLYCYLIC PYRROLYL-AMIDES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
AU2001257146B2 (en) * 2000-04-19 2006-11-30 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
AU2001276607A1 (en) 2002-02-25
CN1446084A (en) 2003-10-01
HUP0300725A3 (en) 2005-11-28
EP1307183A2 (en) 2003-05-07
JP2004506009A (en) 2004-02-26
CA2419033A1 (en) 2002-02-21
WO2002013798A2 (en) 2002-02-21
KR20030023747A (en) 2003-03-19
WO2002013798A3 (en) 2003-01-23
IL154158A0 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
HUP0300725A2 (en) Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
HUP0401998A2 (en) The use of pde 9 inhibitors for production of those medicine being useful in the treatment of insulin resistance syndrome and type 2 diabetes
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
EP1545483A4 (en) Non-nucleoside reverse transcriptase inhibitors
MY138708A (en) Biaryloxymethylarenecarboxylic acids
BR0308904A (en) Method of treatment of gastroparesis and use of a glp-1 compound
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
ME00578A (en) Use of gastrointestinal lipase inhibitors
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
TNSN05065A1 (en) Use of prebiotics for the treatment and prevention of hyperglycaemic syndromes
NO20035602D0 (en) A composition comprising a PDE-4 inhibitor and H1 receptor antagonist, as well as its use in the preparation of a medicament for the treatment of respiratory diseases.
EP1452176A4 (en) Insulin resistance improving agents
EP1422240A3 (en) Analogs of nociceptin
EE05211B1 (en) Use of saredutant and its pharmaceutically acceptable salts in the preparation of medicaments useful for the treatment or prevention of mood disorders, adaptive disorders, or mixed depressive disorders.
BRPI0410761A (en) leucine, and composition for enteral administration to patients
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
WO2005107467A3 (en) Compositions including opioids and methods of their use in treating pain
MXPA05006408A (en) Deuterated catecholamine derivatives and medicaments comprising said compounds.
WO2008068778A8 (en) Extended release pharmaceutical composition of pramipexole
WO2007077454A3 (en) A therapeutic composition comprising an inhibitor of an hsp 90 protein
MXPA04005033A (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.
DK2014290T3 (en) Use of tenatoprazole in the treatment of gastroesophageal reflux
HUP0402645A2 (en) Pharmaceutical composition comprising a glitazone and 4-oxobutanoic acid, and the use thereof for treating diabetes
MXPA04006269A (en) Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees